Drug Supply Chain Security Act (DSCSA)

What is Drug Supply Chain Security Act (DSCSA)?

The Drug Supply Chain Security Act (DSCSA) is a U.S. federal law, enacted in 2013, which establishes a framework for identifying, tracing, and verifying prescription drugs at the package level as they move across the supply chain—from manufacturers to dispensers.

Its goal is to prevent counterfeit, stolen, contaminated, or otherwise harmful drugs from entering the U.S. market.

Why is DSCSA Important for Pharma Supply Chains?

• Patient safety: Ensures only legitimate medicines reach patients by stopping counterfeit or adulterated drugs.
• Regulatory compliance & market access: Pharma manufacturers, distributors, and traders who wish to operate in or with the U.S. must comply with DSCSA requirements. Non‑compliance can block access or result in penalties.
• Transparency & traceability: Enables electronic, interoperable systems for tracing drugs via serialized identifiers, transaction histories, and statements.
  
• Supply chain integrity: Strengthens trust among trading partners (manufacturers, repackagers, dispensers, third‑party logistics) by ensuring each link is accountable and traceable.

What are the Core Principles of DSCSA?

• Serialization: Each lowest saleable unit of a prescription drug must carry a unique identifier (product identifier), including GTIN (Global Trade Item Number), serial number, lot/batch number, and expiration date.
• Transaction Information, Transaction History, Transaction Statement (TI/TH/TS): At every transfer of ownership, stakeholders provide data about who handled the product, what it is, and its movement through the chain.
• Authorized Trading Partners: All parties in the supply chain must be licensed, registered, or otherwise legally authorized to handle prescription drugs.
  
• Verification & Investigation: Entities must be able to verify product identifiers, investigate suspect or illegitimate products, quarantine or remove them if needed.
• Electronic Interoperability: Use of secure, interoperable, electronic systems or standards to exchange transaction data. This includes readiness for machine-readable identifiers and data standards such as EPCIS.
• Phased Implementation / Deadlines: DSCSA was structured over a multiyear timeline with specific implementation milestones culminating in full serialization and traceability by certain deadlines for many requirements.

How DSCSA Works in Practice?

1. Product Serialization & Labeling: Manufacturers (and repackagers) apply unique product identifiers at the package/case level per DSCSA specifications. Dispensers and wholesalers need to accept, store, and use these serialized products.
2. Transaction Data Capture and Sharing: At each change of ownership, the previous owner shares Transaction Information (what the product is), Transaction History (where it has been), and a Transaction Statement (asserting compliance). These must be maintained in a format suitable for interoperable electronic exchange.
3. Verification of Trading Partners: Every entity (manufacturer, wholesaler, dispenser, repackager, logistics provider) must confirm that their counterparties are licensed (or legally authorized) under DSCSA or state/local authorities.
4. Monitoring & Handling Illegitimate Products: If a product is suspected to be counterfeit, adulterated, or otherwise illegitimate (“suspect product”), parties must investigate. If confirmed, the product must be quarantined or removed from the supply chain, and reporting to the FDA or the appropriate authorities must be made.
5. Electronic Infrastructure & Interoperability: Systems, standards, and identifiers (like GTIN, GLN) are used to enable secure exchanging, tracing, and verifying of data across supply chain actors. Labeling may include barcodes or data matrix codes.
6. Compliance & Deadlines: DSCSA mandates phases for implementation, with deadlines for serialization, product tracing, and enhanced traceability. Entities must meet those deadlines. As of November 27, 2023, many of the requirements for serialized, unit-level traceability came into effect.

Related Terms and Concepts

• Serialization – assigning unique identifiers to individual product units for traceability.
• GTIN / GLN – Global Trade Item Number and Global Location Number used for product and partner identification.
• Traceability – The ability to track and trace the path of drugs through the supply chain.
• Authorized Trading Partner – Entities legally allowed under DSCSA to handle prescription drugs.
• Suspect / Illegitimate Product – Products that fail verification or arouse suspicion of counterfeiting or tampering.
• Electronic Interoperability / EPCIS – Data standards for exchanging traceability/transaction data.

Drug Supply Chain Security Act FAQs

What products are exempt from DSCSA requirements?

DSCSA excludes certain prescription drug types like active pharmaceutical ingredients (APIs), medical gases, imaging drugs, some intravenous fluids, radioactive drugs and others specified by law.

Who must comply under DSCSA?

Manufacturers, repackagers, wholesale distributors, third‑party logistics providers, and dispensers in the U.S., along with partners trading with them for prescription drug shipments.

What is serialization in the context of DSCSA?

Serialization under DSCSA means assigning each smallest saleable unit a product identifier (GTIN + serial number + lot number + expiration date) for traceability and verification.

What is the interoperable, electronic trace‑exchange requirement?

DSCSA requires secure electronic systems that allow trading partners to exchange transaction data, including TI, TH, and TS, in standard formats for verification and traceability.

When did full DSCSA serialized item‑level traceability become required?

Many DSCSA requirements, including serialized item‑level traceability, came into force by November 27, 2023.

What data must be retained and for how long?

Trading partners must maintain transaction history, transaction information, and statements related to prescriptions; pharmacies must keep records (e.g., six years in many states).

Do trading partners outside the U.S. need DSCSA compliance?

Yes—if exporting prescription drugs into the U.S., companies must meet DSCSA requirements (serialization, documentation, authorized partner status) to avoid regulatory or customs issues.

How does DSCSA define “Authorized Trading Partner”?

An “Authorized Trading Partner” under DSCSA is a manufacturer, repackager, wholesale distributor, third‑party logistics provider, or dispenser that is appropriately licensed, registered, or meets legal authorization requirements.

What are the consequences of non‑compliance with DSCSA?

Failures to comply can lead to FDA actions, suspension of licensure, product recalls or removal, and possibly civil or criminal penalties, depending on the severity.

How does DSCSA improve supply chain transparency?

By requiring serialization, standardized identifiers (GTIN, GLN), electronic transaction data, and traceability at the package level, DSCSA makes the provenance and movement of drugs visible and verifiable throughout the chain.